Drug Profile
Budesonide/formoterol - Pearl Therapeutics
Alternative Names: BFF MDI; Budesonide and formoterol (BFF MDI) - Pearl Therapeutics; Formoterol/budesonide - Pearl Therapeutics; PT-009Latest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator Pearl Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
Most Recent Events
- 18 Mar 2022 Budesonide/formoterol is still in phase III development for Chronic obstructive pulmonary disease (Treatment-experienced) in Germany
- 30 Dec 2020 AstraZeneca completes a phase III clinical trial in Chronic obstructive pulmonary disease (Treatment-experienced) in Germany (Inhalation) (NCT04078126)
- 10 Sep 2019 Phase-III clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in Germany (Inhalation) (NCT04078126)